Alexandria Real Estate Equities, Inc. research snapshot
ARE AI stock analysis currently reads Alexandria Real Estate Equities as a specialized life science REIT with strong tenant assets but low investment certainty until occupancy, capital recycling, and debt metrics stabilize. At the July 8, 2026 cutoff, ARE closed at $49.41 on July 7, 2026, market capitalization was about $8.61 billion, and the stock traded at roughly 0.54x book value with a 9% plus dividend yield. The AI stock forecast is scenario-based because reported earnings are distorted by real estate impairments, while adjusted FFO, leasing progress, asset sales, and the 2026 occupancy guide are more useful for tracking the thesis. This page is informational research and not investment advice.
Current price
$49.41
Market cap
$8.61 billion
AI score
58 / 100
Rating
High-quality life science REIT under balance sheet stress
Trend status
Recovering near the 50-day average but still below the 200-day average
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | ARE owns specialized life science, laboratory, and technology campuses in major innovation clusters. The properties are hard to replicate, but recent occupancy and same-property NOI pressure show that demand is cyclical. | Medium-high |
| Moat | The moat comes from cluster locations, lab infrastructure, tenant relationships, scale, zoning scarcity, and operating know-how. It is not immune to tenant funding cycles or competing sublease supply. | Medium |
| Management | Management is focused on cost reduction, asset sales, reducing capital spend, and protecting liquidity. The key capital allocation test is whether these moves reduce leverage without permanently damaging earnings power. | Medium |
| Financial trend | 2025 revenue was $3.027 billion, but common-stockholder net loss was $1.217 billion after large impairment pressure. TTM revenue fell to $2.939 billion and Q1 2026 adjusted FFO per share was $1.73. | High |
| Valuation | At $49.41, ARE traded near 0.54x book value and around 5.9x trailing adjusted FFO using the verified $8.44 TTM adjusted FFO per share bridge. The discount is large, but it reflects leverage, occupancy, and dividend risk. | Medium-high |
| Technical trend | ARE is slightly above its 50-day moving average but below its 200-day moving average, which points to a short-term rebound inside a still-damaged longer-term trend. | Medium |
| Risk level | Risk is elevated for a REIT because net debt is large, total debt is above $12 billion, occupancy guidance was reduced, same-property NOI is expected to decline, and the dividend yield signals market skepticism. | Medium-high |
| AI confidence | High for quote math, share count, company filings, 2025 financials, Q1 2026 operating data, and technical inputs; medium for leasing recovery timing and private life science funding conditions. | High data confidence |
| Investment certainty | Medium-low certainty. The asset base has quality, but the margin of safety depends on a business recovery rather than a simple low multiple. | Medium-low |
ARE AI stock forecast
The ARE AI stock forecast uses adjusted FFO, book value, occupancy, and leverage rather than GAAP EPS alone. The bullish case requires evidence that lab leasing improves, asset sales occur at acceptable cap rates, debt metrics decline, and the dividend is fundable. The bearish case becomes more likely if 2026 occupancy, same-property NOI, or disposition assumptions weaken again.
$65 to $75
More likely if ARE stabilizes occupancy, delivers leased space into revenue, keeps liquidity above stress levels, reduces net debt through dispositions, and investors re-rate the stock toward a higher FFO multiple. The verified three-scenario model produced about $73.80 using 3% adjusted FFO growth and an 8x terminal multiple.
$47 to $55
More likely if ARE remains a repair story: adjusted FFO holds near the current run rate, dividend pressure is contained, the 200-day moving average remains overhead resistance, and the market waits for proof of a leasing recovery. The model base case was about $50.60.
$24 to $35
More likely if life science tenant demand weakens further, same-property NOI declines beyond guidance, asset sales require discounts, debt costs stay high, or the dividend is reset again. The verified bear model produced about $24.60 using lower adjusted FFO and a 4x multiple.
ARE AI technical analysis
ARE AI technical analysis starts from the $49.41 close on July 7, 2026. The stock is above its 50-day moving average of $48.86 but below its 200-day moving average of $54.62, so the chart shows a short-term bounce that has not yet repaired the longer-term downtrend. Technical levels should be checked against REIT rates, earnings updates, dividend news, and leasing disclosures.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $49.41 | Latest verified close used for this page, reported for July 7, 2026. |
| Near support | $48.86 | The 50-day moving average is the first support reference. A failure back below it would weaken the rebound setup. |
| Secondary support | $42 to $45 | Recent 2026 lows and spring trading zones matter if the stock loses the 50-day average after earnings or rate news. |
| Near resistance | $51 to $52 | This range sits near the StockAnalysis average analyst target of $51.36 and recent trading congestion. |
| 200-day moving average | $54.62 | A sustained move above the 200-day average would be the first technical sign that longer-term trend damage is improving. |
| Momentum | RSI 44.23 | RSI is neither oversold nor strongly bullish. Momentum is still fragile. |
| Volume | 20-day average 1.91 million shares | Volume expansion near earnings or dividend announcements should be checked for institutional repositioning. |
| Volatility | Beta 1.18 | ARE has been more volatile than the broad market, which is unusual for a defensive REIT label and reflects current stress. |
| Invalidation | Close below $48 or adverse guidance cut | A decisive close below the 50-day average, a lower occupancy guide, or weaker disposition pricing would weaken the base case. |
ARE AI trading strategy
The ARE AI trading strategy is a rules-based REIT turnaround framework, not personalized advice. It should be monitored through live price, interest rates, leasing updates, dividend coverage, disposition proceeds, liquidity, and Q2 2026 earnings.
Wait for price to hold above the 50-day moving average and then challenge the 200-day moving average while company updates show stable occupancy, better leasing, and no further guidance cut.
Reduce confidence if price fails below $48, adjusted FFO guidance declines, or management needs larger asset sales at weak pricing.
Use the discount to book value and low FFO multiple as a watchlist signal only when paired with improving REIT rates and evidence that lab demand is not worsening.
Do not treat a low price-to-book ratio as a floor. Real estate impairments can keep book value moving lower.
Track dividend yield, common dividends paid, operating cash flow, capital expenditure needs, debt maturities, asset-sale proceeds, and liquidity.
A dividend reset, weaker liquidity, or rising debt costs can override a bullish chart setup.
Investment research summary
Alexandria is paid to provide specialized lab, office, and campus infrastructure to pharmaceutical, biotechnology, biomedical, technology, and institutional tenants. Customers pay for location, lab readiness, ecosystem access, and operational reliability.
The moat is strongest in cluster locations such as Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, and Research Triangle. It comes from scarce lab-ready assets, tenant relationships, campus density, and real estate execution. The moat narrows when tenant funding, vacancy, or capital costs become the dominant issue.
The thesis can fail if lab demand remains weak, tenants downsize, occupancy falls below guidance, impairments continue, asset sales occur at poor values, debt markets tighten, or the dividend consumes too much cash.
Management is trying to move from growth funding to balance-sheet repair through cost cuts, lower capital spend, and dispositions. The important test is whether capital recycling preserves the best campuses and reduces leverage fast enough.
The long-term need for life science research infrastructure remains real, but the near-term cycle depends on biotech funding, pharma budgets, rate levels, and tenant utilization. AI-enabled biology may support demand over time, but it does not remove current vacancy risk.
The verified model produced about $73.80 in the bull case, $50.60 in the base case, and $24.60 in the bear case using adjusted FFO scenarios. The margin of safety is conditional on operating stabilization, not only on a low book multiple.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ARE price | $49.41 close on July 7, 2026 | StockAnalysis statistics page | July 8, 2026 |
| Market capitalization | $8.61 billion, verified as $49.41 x 174.27 million shares | financial_rigor.py market cap verification | July 8, 2026 |
| Shares outstanding | 174.27 million | StockAnalysis statistics page | July 8, 2026 |
| 2025 revenue | $3.027 billion, cross-validated against StockAnalysis, Macrotrends, and ARE annual report data | ARE 2025 Annual Report | July 8, 2026 |
| 2025 net loss | $1.217 billion net loss, cross-validated against StockAnalysis, Macrotrends, and ARE annual report data | Macrotrends net income page | July 8, 2026 |
| Q1 2026 adjusted FFO per share | $1.73 per diluted share, with $295.9 million of adjusted FFO | ARE 1Q26 results release | July 8, 2026 |
| Q1 2026 occupancy | 88.9% average occupancy, down from 94.0% in the same prior-year period | ARE 1Q26 results release | July 8, 2026 |
| Q1 2026 cash and debt | $418.7 million cash and equivalents, about $12.52 billion total debt and preferred stock | ARE 1Q26 supplemental package | July 8, 2026 |
| Technical indicators | 50-day MA $48.86, 200-day MA $54.62, RSI 44.23, 20-day average volume 1.91 million | StockAnalysis statistics page | July 8, 2026 |
| Analyst consensus | Hold consensus from 16 analysts, average price target $51.36 | StockAnalysis statistics page | July 8, 2026 |
This ARE AI stock analysis page is an informational tool only and is not investment advice, tax advice, or a recommendation to buy or sell any security. Forecast ranges are scenarios based on available public data as of July 8, 2026 and may be wrong if financial results, rates, tenant demand, asset values, or market conditions change.
